Pain Control Following Total Hip Arthroplasty

NCT ID: NCT05062356

Last Updated: 2024-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-04

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Total hip arthroplasty (THA) is one of the most common surgical procedures performed in elderly patients, with its main indication being end-stage osteoarthritis of the hip1. It is estimated that over 572,000 patients per year will undergo THA in the USA alone by 20301 and postsurgical pain associated with THA remains a significant issue. Postoperative pain is associated with delayed joint mobilization, ambulation, patient satisfaction and can often delay the patient's discharge home1.

Multimodal analgesia for the management of postoperative pain following THA is now standard of care2,3. It involves a combination of local anesthetic infiltration (LAI), peripheral nerve blocks (PNBs), analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen and/or other medications, including gabapentinoids and opioids. Using multiple analgesic modalities allows for an easier and faster recovery for THA patients and ultimately allows for reduction in postoperative narcotic use and it's associated negative side effects. Total hip arthroplasty can be performed under either general anesthesia, epidural anesthesia or most commonly under spinal anesthesia, with or without epidural morphine. The adjunctive use of LAI, pericapsular nerve group (PENG) block or suprainguinal fascia iliaca compartment block (FICB) for postoperative pain management is becoming more widespread, although evidence on their efficacy has been inconsistent4-8. As such, comparative evaluation of these adjuctive analgesic modalities is imperative to optimize postoperative pain management following THA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve9. The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus. Evidence to date shows that FICB and PENG may be effective modalities to provide postoperative pain control following THA and could reduce opioid consumption10. The above procedures have been documented as safe and effective when performed by a qualified anesthetist but come with various risks (potential motor / sensory blocade especially) and associated cost. Alternatively, or in conjunction to the above procedures, the orthopedic surgeon can perform local anaesthetic infiltration (LAI) into the anterior pericapsular tissues. To date, no study has compared the efficacy of FICB, PENG block and LAI in a randomized study, therefore a preferred postoperative analgesic regimen has yet to be determined.

In this randomized trial, the investigators aim to evaluate postoperative pain and side effects related to pain control in patients who receive FICB versus LAI versus PENG block following THA. The investigators aim to compare these procedures between each other and assertain whether these techniques compare favourably to spinal anesthetic as a control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suprainguinal fascia iliaca compartment block (FICB)

Suprainguinal fascia iliaca compartment block (FICB) is a technique that involves injection of local anesthetics underneath the fascia of the iliacus muscle to block the femoral nerve, the lateral femoral cutaneous nerve and, possibly, the obturator nerve.

Group Type EXPERIMENTAL

Bupivacaine Hydrochloride 0.25% Injection Solution_#2

Intervention Type DRUG

40cc

EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge

Intervention Type DRUG

10cc

Ketorolac

Intervention Type DRUG

15mg

Pericapsular nerve group block (PENG)

The pericapsular nerve group block (PENG) is a technique that involves injection of local anesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus.

Group Type ACTIVE_COMPARATOR

EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge

Intervention Type DRUG

10cc

Bupivacaine Hydrochloride 0.5% Injection Solution_#2

Intervention Type DRUG

20cc

Ketorolac

Intervention Type DRUG

15mg

Local analgesia infiltration (LAI)

local anesthetic infiltration (LAI) into the anterior pericapsular tissues

Group Type SHAM_COMPARATOR

Bupivacaine Hydrochloride 0.25% Injection Solution_#2

Intervention Type DRUG

40cc

EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge

Intervention Type DRUG

10cc

Ketorolac

Intervention Type DRUG

15mg

No adjunct: spinal anaesthesia (control)

Standard spinal anesthesia technique

Group Type SHAM_COMPARATOR

Bupivacaine Hydrochloride 0.5% Injection Solution_#2

Intervention Type DRUG

20cc

Ketorolac

Intervention Type DRUG

15mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupivacaine Hydrochloride 0.25% Injection Solution_#2

40cc

Intervention Type DRUG

EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge

10cc

Intervention Type DRUG

Bupivacaine Hydrochloride 0.5% Injection Solution_#2

20cc

Intervention Type DRUG

Ketorolac

15mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (≥18 years old) who require an inpatient primary total hip arthroplasty under spinal anesthesia
* Written consent
* Any gender

Exclusion Criteria

* Patients who require revision surgery
* Anesthesia other than spinal (general, epidural, other)
* Body mass index (BMI) \> 45 kg/m2
* Allergies to study medication
* Previous fracture to affected area
* Previous surgery to the affected hip
* Diagnosis other than osteoarthritis (avascular necrosis, significant deformity such as post-Perthes, slipped capital femoral epiphysis, dysplasia classified as Crowe 3 or 4, or other diagnoses causing significant deformity of the femoral head or acetabulum)
* THA for hip fractures
* Patients taking daily opiod analgesics pre-operatively
* Anesthetist on day of surgery who does not perform FICB and PENG and no alternate anesthetist available to perform the block
* Patients who do not understand, read or communicate in either French or English
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Mary's Research Center, Canada

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anthony Albers, MD

MD, Orthopaedic Surgeon

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Anthony Albers, MDCM, FRCSC

Role: PRINCIPAL_INVESTIGATOR

McGill University, Department of Surgery

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Mary's Hospital Center

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMHC - 21- 02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.